A Phase I/II, Open-Label Single Institution Study Evaluating Rapamycin in Combination With High-Dose Etoposide and Cytarabine in Relapsed or Refractory Aggressive Lymphoid Malignancies

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 31 Mar 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Cytarabine (Primary) ; Etoposide (Primary) ; Sirolimus (Primary)
Indications Burkitt's lymphoma; Chronic myeloid leukaemia; Lymphoid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms UPCC 25406

29 Sep 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
12 Nov 2008 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com